Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy with volasertib

A technology of voracertide and composition, which is applied in the directions of drug combination, medical preparation containing active ingredients, peptide/protein ingredients, etc., can solve the problem of indistinguishable

Inactive Publication Date: 2015-07-29
BOEHRINGER INGELHEIM INT GMBH
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As this is a mammalian cell expression system, Legrastim is indistinguishable from native human GCSF of 174 amino acids

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0088] For example, administration of voracetib on at least 1 day and at most 5 days during a 6-day treatment cycle means that voracetib can be administered once or up to 5 times during said period, wherein only one dose per day is administered. For example it may be administered on day 1 only, or it may be administered on days 1, 3 and 5. It can also be administered on days 1 to 5 or only on days 1 and 5.

[0089] The above treatments can be repeated as long as the patient is eligible for repeat cycles (ie, until progression of disease) and neither the patient nor the investigator requests discontinuation of treatment.

[0090] Instructions for the administration of the combination may be in any pharmaceutically suitable form, for example in the form of a printed leaflet affixed to the secondary packaging, or printed on the primary or secondary packaging.

[0091]Those skilled in the art know that it may optionally be necessary to deviate from the indicated amounts of volace...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is the use of Volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising administering a high dose of Volasertib in combination with fludarabine, cytarabine and Granulocyte colony-stimulating factor (GCSF) or in combination with fludarabine, cytarabine, GCSF and a daunorubicin citrate liposome injection.

Description

[0001] The present invention relates to the use of volasertib or its salt or hydrate for treating patients suffering from acute myelogenous leukemia (AML), comprising combining high doses of volasertib with fludarabine, albino Combination of cytidine and granulocyte colony-stimulating factor (GCSF), or high-dose voracetib with fludarabine, cytarabine, GCSF, and daunorubicin citrate liposomal injection . Background of the invention [0002] Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid lineage of blood cells characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the Production of normal blood cells. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated. AML is the most prevalent form of leukemia in adults, especially the elderly, and is slightly more common in men than women. There are an estimated 30,000 c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/19A61K31/519A61K31/704A61K31/7076C07K14/535A61P35/02
CPCA61K38/193A61K31/704A61K31/7068A61K31/519A61K31/7076A61P35/02A61P43/00A61K2300/00A61K9/127
Inventor T·陶布
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com